coadministered cagrilintide and semaglutide in adults with overweight or obesity PDF] Once-weekly for weight management people obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Cagrilintide & Semaglutide in Overweight

This is a critical distinction between research evidence and regulatory approval, and it affects legal status, availability, and the framework within which these compounds can be used

References, sources and studies used alongside our own in-house research have been cited below, most of which contain external clickable links to reviewed scientific paper that contain date stamped evidence

Both are preclinical and investigational, not approved for human or veterinary use

Subcutaneous (SubQ): This involves using a short, fine-gauge needle (like an insulin needle) to inject the solution into the fatty layer of tissue just beneath the skin